Antidepressant provides a cool choice for hot flashes

February 12, 2002

Mayo Clinic study confirms venlafaxine is safe, effective for women with and without breast cancer

ROCHESTER, MINN. -- A Mayo Clinic study indicates long-term use of the antidepressant drug venlafaxine provides women treated for breast cancer with safe and effective relief from hot flashes. It also appears that this antidepressant can be an alternative to estrogen for women who want a nonhormonal treatment for their hot flashes.

This follow-up study showed that women receiving venlafaxine over eight weeks maintained approximately a 60 percent reduction in their hot flashes. A total of 102 postmenopausal women participated in this investigation. The findings of the eight-week evaluation mirrored the results of the first phase of this study -- a four-week double-blinded, randomized study that involved more than 200 women.

The results of the study are published in the current edition of Oncology Nursing Forum.

"The clear message is that now many women with breast cancer do not have to suffer with their hot flashes and that women who want a non-estrogenic choice of treatment now have one," says Charles Loprinzi, M.D., a Mayo Clinic oncologist.

"The study also further reassures physicians and other health care providers that venlafaxine is a safe and effective nonhormonal treatment they can consider for their postmenopausal patients."

Dr. Loprinzi co-authored this study with Debra L. Barton, Ph.D., a Mayo Clinic oncology nurse researcher.

"We know from our previous study that venlafaxine works in the short term to control hot flashes," says Dr. Barton. "This follow-up study provides evidence that venlafaxine continues to be effective and well tolerated over a longer period of time."

Hot flashes are a major problem for many postmenopausal women. In women without breast cancer, hormone replacement therapy involving estrogen is the typical treatment prescribed to relieve the problem.

That is not the case for women with breast cancer. Frequently, the chemotherapy used to treat the cancer causes the woman to go into early menopause and experience severe hot flashes. Because of the concern that estrogen may lead to the growth of breast cancer cells, these women are often denied estrogen for hot flashes.

The newer antidepressants, of which venlafaxine is one, offer more hope for nonhormonal management of hot flashes. These newer antidepressants work to control various neurotransmitters in the brain. Some of those neurotransmitters are thought to trigger hot flashes.

"In a dose of 75 mg per day, extended-release venlafaxine offered an average 60 percent reduction in the frequency of hot flashes," says Dr. Loprinzi. "Women in both studies also noted that venlafaxine seemed to reduce the severity of their hot flashes."

The side effects of venlafaxine include mild appetite loss, dry mouth and, in some women, nausea. Of the minority of women in this study experiencing nausea from venlafaxine, most rated their nausea as relatively mild and transitory. In about 10 percent of the women, nausea was a more prominent problem.
-end-
Mary Lawson
507-284-5005 (days)
507-284-2511 (evenings)
e-mail: newsbureau@mayo.edu

Mayo Clinic

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.